Search for a report

NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028

  • You are here:
  • Home
  • Downloads
  • NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028

NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028

The North America irritable bowel syndrome treatment market is projected to record a CAGR of 6.36% during the forecast period, 2021-2028. The growing prevalence of irritable bowel syndrome and related conditions and the rising number of FDA approvals & drug developments are propelling the market growth. The North America irritable bowel syndrome treatment market growth assessment includes the analysis of the United States and Canada. According to the 2017 FDA data, there is a high prevalence of irritable bowel syndrome (IBS).

NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028

North America Irritable Bowel Syndrome Treatment Market by Type (Ibs With Diarrhea, Ibs With Constipation, Mixed Ibs) by Product (Rifaximin, Eluxadoline, Linaclotide, Lubiprostone, Other Products) by Distribution Channel (Drug Stores and Retail Pharmacies, Hospitals’ Pharmacies, Online Pharmacies) by Mechanism of Action (5ht3 Antagonist, Guanylate Cyclase Receptor-c Agonist, Chloride Channel Activator, Other Mechanism of Actions) by Dosage (Solid, Liquid) and by Geography

Request free sample

The North America irritable bowel syndrome treatment market is projected to record a CAGR of 6.36% during the forecast period, 2021-2028. The growing prevalence of irritable bowel syndrome and related conditions and the rising number of FDA approvals & drug developments are propelling the market growth.

To learn more about this report, request a free sample copy

The North America irritable bowel syndrome treatment market growth assessment includes the analysis of the United States and Canada. According to the 2017 FDA data, there is a high prevalence of irritable bowel syndrome (IBS). IBS with diarrhea (IBS-D), IBS with mixed bowel habits (diarrhea and constipation), and IBS with constipation (IBS-C), are the three types of IBS. Among these, IBS-M (IBS mixed bowel habits) is prominent among the geriatric population. Also, it does not have a medical cure. It can only be treated through lifestyle changes and diet patterns. At the same time, severe conditions like diarrhea, cramping, excessive gas, and abdominal pain are medically treatable. Several pharmaceutical products are used to treat IBS-D with a lack of approvals by the FDA. Moreover, few products approved by FDA are restricted to use only for women. As a result, to minimize chronic health conditions, FDA has published guidance for companies to evaluate the clinical status. The clinical status is majorly dependent on symptoms and signs related to IBS. The guidance includes PRO (patient-reported outcome measures), which will aid in developing medical products. Such developments are estimated to be beneficial to market growth in the United States.

Bausch Health Companies, formerly Valeant Pharmaceuticals, develops, markets, and manufactures a vast range of products in gastrointestinal disorders, dermatology, neurology, branded generics, etc. The company’s strong focus on research & development capabilities allows it to offer differentiated products. It is headquartered in Laval, Quebec, Canada.

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      •    KEY DRIVERS
        • RISE IN THE INCIDENCE OF GASTROINTESTINAL AILMENTS
        • GROWING NUMBER OF DRUG DEVELOPMENTS AND FDA APPROVALS
        • SURGING OCCURENCE OF IRRITABLE BOWEL SYNDROME
        • INCREASING GERIATRIC POPULATION
      •    KEY RESTRAINTS
        • HIGH COST OF DRUGS
        • LIMITED TREATMENT OPTIONS
    1. KEY ANALYTICS
      •    PORTER’S FIVE FORCES ANALYSIS
        • THREAT OF NEW ENTRY
        • THREAT OF SUBSTITUTION
        • BUYER’S POWER
        • SUPPLIER’S POWER
        • COMPETITIVE RIVALRY
      • IMPACT OF COVID-19 ON IRRITABLE BOWEL SYNDROME TREATMENT MARKET
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • KEY INVESTMENT INSIGHTS
    2. MARKET BY TYPE
      • IBS WITH DIARRHEA
      • IBS WITH CONSTIPATION
      • MIXED IBS
    3. MARKET BY PRODUCT
      • RIFAXIMIN
      • ELUXADOLINE
      • LINACLOTIDE
      • LUBIPROSTONE
      • OTHER PRODUCTS
    4. MARKET BY DISTRIBUTION CHANNEL
      • DRUG STORES AND RETAIL PHARMACIES
      • HOSPITALS’ PHARMACIES
      • ONLINE PHARMACIES
    5. MARKET BY MECHANISM OF ACTION
      • 5HT3 ANTAGONIST
      • GUANYLATE CYCLASE RECEPTOR-C AGONIST
      • CHLORIDE CHANNEL ACTIVATOR
      • OTHER MECHANISM OF ACTIONS
    6. MARKET BY DOSAGE
      • SOLID
      • LIQUID
    7. GEOGRAPHICAL ANALYSIS
      •    NORTH AMERICA
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        •    COUNTRY ANALYSIS
          • UNITED STATES
          • CANADA
    1. COMPETITIVE LANDSCAPE
      •    KEY STRATEGIC DEVELOPMENTS
        • MERGER & ACQUISITIONS
        • PRODUCT LAUNCH & DEVELOPMENTS
        • PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
        • BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
      •    COMPANY PROFILE
        • ABBOTT LABORATORIES
        • BAUSCH HEALTH COMPANIES INC
        • ALLERGAN PLC
        • ARDELYX INC
        • ASTELLAS PHARMA INC
        • ASTRAZENECA PLC
        • GLAXOSMITHKLINE PLC
        • IRONWOOD PHARMACEUTICALS INC
        • JOHNSON & JOHNSON (MCNEIL CONSUMER HEALTHCARE)
        • LANNETT COMPANY INC
        • NOVARTIS AG
        • SEBELA PHARMACEUTICALS INC
        • SYNTHETIC BIOLOGICS INC
        • TAKEDA PHARMACEUTICAL COMPANY LTD

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – IRRITABLE BOWEL SYNDROME TREATMENT

    TABLE 2: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 3: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 4: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 5: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 6: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 7: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 8: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 9: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 10: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 11: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 12: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 13: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 14: LEADING PLAYERS OPERATING IN NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET

    LIST OF FIGURES

    FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

    FIGURE 2: OPPORTUNITY MATRIX

    FIGURE 3: VENDOR LANDSCAPE

    FIGURE 4: KEY INVESTMENT INSIGHTS

    FIGURE 5: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, IN 2020

    FIGURE 6: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH DIARRHEA, 2021-2028 (IN $ MILLION)

    FIGURE 7: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH CONSTIPATION, 2021-2028 (IN $ MILLION)

    FIGURE 8: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MIXED IBS, 2021-2028 (IN $ MILLION)

    FIGURE 9: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, IN 2020

    FIGURE 10: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY RIFAXIMIN, 2021-2028 (IN $ MILLION)

    FIGURE 11: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ELUXADOLINE, 2021-2028 (IN $ MILLION)

    FIGURE 12: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LINACLOTIDE, 2021-2028 (IN $ MILLION)

    FIGURE 13: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LUBIPROSTONE, 2021-2028 (IN $ MILLION)

    FIGURE 14: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER PRODUCTS, 2021-2028 (IN $ MILLION)

    FIGURE 15: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, IN 2020

    FIGURE 16: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DRUG STORES AND RETAIL PHARMACIES, 2021-2028 (IN $ MILLION)

    FIGURE 17: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY HOSPITALS’ PHARMACIES, 2021-2028 (IN $ MILLION)

    FIGURE 18: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ONLINE PHARMACIES, 2021-2028 (IN $ MILLION)

    FIGURE 19: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, IN 2020

    FIGURE 20: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY 5HT3 ANTAGONIST, 2021-2028 (IN $ MILLION)

    FIGURE 21: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY GUANYLATE CYCLASE RECEPTOR-C AGONIST, 2021-2028 (IN $ MILLION)

    FIGURE 22: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY CHLORIDE CHANNEL ACTIVATOR, 2021-2028 (IN $ MILLION)

    FIGURE 23: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER MECHANISM OF ACTIONS, 2021-2028 (IN $ MILLION)

    FIGURE 24: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, IN 2020

    FIGURE 25: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY SOLID, 2021-2028 (IN $ MILLION)

    FIGURE 26: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LIQUID, 2021-2028 (IN $ MILLION)

    FIGURE 27: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

    FIGURE 28: UNITED STATES IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

    FIGURE 29: CANADA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

    1. GEOGRAPHICAL ANALYSIS
      •    NORTH AMERICA
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        •    COUNTRY ANALYSIS
          • UNITED STATES
          • CANADA
    1. MARKET BY TYPE
      • IBS WITH DIARRHEA
      • IBS WITH CONSTIPATION
      • MIXED IBS
    2. MARKET BY PRODUCT
      • RIFAXIMIN
      • ELUXADOLINE
      • LINACLOTIDE
      • LUBIPROSTONE
      • OTHER PRODUCTS
    3. MARKET BY DISTRIBUTION CHANNEL
      • DRUG STORES AND RETAIL PHARMACIES
      • HOSPITALS’ PHARMACIES
      • ONLINE PHARMACIES
    4. MARKET BY MECHANISM OF ACTION
      • 5HT3 ANTAGONIST
      • GUANYLATE CYCLASE RECEPTOR-C AGONIST
      • CHLORIDE CHANNEL ACTIVATOR
      • OTHER MECHANISM OF ACTIONS
    5. MARKET BY DOSAGE
      • SOLID
      • LIQUID

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


      Choose License Type

      Buy Now